BRCA1/2 and Endometrial Cancer Risk: Implications for Management.
作者信息
Sherman Mark E, Foulkes William D
机构信息
Quantitative Health Sciences, Mayo Clinic College of Medicine, Jacksonville, FL, USA.
Department of Medicine, Human Genetics and Oncology, McGill University, Montreal, Quebec, Canada.
出版信息
J Natl Cancer Inst. 2021 Sep 4;113(9):1127-1128. doi: 10.1093/jnci/djab037.
Abstract
摘要
相似文献
1
BRCA1/2 and Endometrial Cancer Risk: Implications for Management.BRCA1/2与子宫内膜癌风险：对治疗的启示
J Natl Cancer Inst. 2021 Sep 4;113(9):1127-1128. doi: 10.1093/jnci/djab037.
2
RE: Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.关于：携带种系BRCA1或BRCA2突变女性的子宫内膜癌风险：多中心队列研究。
J Natl Cancer Inst. 2022 Feb 7;114(2):320-321. doi: 10.1093/jnci/djab154.
3
BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.BRCA1和BRCA2致病变异携带者与子宫内膜癌风险：一项队列研究。
Eur J Cancer. 2020 Sep;136:169-175. doi: 10.1016/j.ejca.2020.05.030. Epub 2020 Jul 19.
4
Endometrial Cancer, BRCA1, and BRCA2 in the UK Biobank Cohort.英国生物库队列中的子宫内膜癌、BRCA1 和 BRCA2
Am J Clin Oncol. 2021 Jul 1;44(7):299-300. doi: 10.1097/COC.0000000000000833.
5
Association of genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 with the risk of endometrial carcinoma and clinicopathological parameters among Chinese Han women.中国汉族女性中AURKA、BRCA1、CCNE1和CDK2基因多态性与子宫内膜癌风险及临床病理参数的相关性
Eur J Obstet Gynecol Reprod Biol. 2015 Jan;184:65-72. doi: 10.1016/j.ejogrb.2014.11.001. Epub 2014 Nov 20.
6
Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer.散发性子宫内膜癌中BRCA1、TP53和TCRD标记杂合性缺失的分析
Eur J Cancer. 1998 Oct;34(11):1770-6. doi: 10.1016/s0959-8049(98)00270-6.
7
Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families.澳大利亚BRCA1和BRCA2基因突变阳性家族中的子宫内膜癌报告。
Twin Res Hum Genet. 2011 Apr;14(2):111-8. doi: 10.1375/twin.14.2.111.
8
Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.BRCA1 和 BRCA2 突变携带者中的口服避孕药使用：绝对癌症风险和获益。
J Natl Cancer Inst. 2022 Apr 11;114(4):540-552. doi: 10.1093/jnci/djac004.
9
The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.BRCAness 在丹麦基于人群的上皮性卵巢癌队列中的临床重要性。
Int J Gynecol Cancer. 2019 Jan;29(1):166-173. doi: 10.1136/ijgc-2018-000017.
10
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.BRCA1 和 BRCA2 基因突变女性的子宫内膜癌发病率：一项国际前瞻性队列研究。
Gynecol Oncol. 2013 Jul;130(1):127-31. doi: 10.1016/j.ygyno.2013.03.027. Epub 2013 Apr 3.
引用本文的文献
1
Identification of clusters related to programmed cell death and potential prognostic biomarkers for immunotherapy response in endometrial cancer.子宫内膜癌中与程序性细胞死亡相关的簇的鉴定及免疫治疗反应的潜在预后生物标志物
Sci Rep. 2025 Jul 1;15(1):22165. doi: 10.1038/s41598-025-06672-9.
2
Estimating Cancer Penetrance in Carriers of BRCA2 Pathogenic Variants Using Cancer-Specific Polygenic Scores.使用癌症特异性多基因评分估计BRCA2致病变异携带者的癌症外显率。
Cancer Med. 2025 Jun;14(11):e70990. doi: 10.1002/cam4.70990.
3
Assessment of NUDT5 in Endometrial Carcinoma: Functional Insights, Prognostic and Therapeutic Implications.子宫内膜癌中NUDT5的评估：功能见解、预后及治疗意义
Biomedicines. 2025 May 7;13(5):1136. doi: 10.3390/biomedicines13051136.
4
Hereditary Women's Cancer: Management and Risk-Reducing Surgery.遗传性女性癌症：管理与降低风险手术。
Medicina (Kaunas). 2023 Feb 6;59(2):300. doi: 10.3390/medicina59020300.
5
Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review.BRCA 突变携带者的降低风险的乳腺和妇科手术：一篇叙述性综述。
J Clin Med. 2023 Feb 10;12(4):1422. doi: 10.3390/jcm12041422.
6
Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.BRCA1/2 相关高级别浆液性妇科恶性肿瘤的降低风险选择。
Curr Oncol. 2022 Mar 21;29(3):2132-2140. doi: 10.3390/curroncol29030172.
7
RE: Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.关于：携带种系BRCA1或BRCA2突变女性的子宫内膜癌风险：多中心队列研究。
J Natl Cancer Inst. 2022 Feb 7;114(2):320-321. doi: 10.1093/jnci/djab154.
8
Response to Nahshon and Lavie.对纳赫松和拉维的回应。
J Natl Cancer Inst. 2022 Feb 7;114(2):322-323. doi: 10.1093/jnci/djab155.
本文引用的文献
1
Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.携带胚系 BRCA1 或 BRCA2 突变的女性的子宫内膜癌风险：多中心队列研究。
J Natl Cancer Inst. 2021 Sep 4;113(9):1203-1211. doi: 10.1093/jnci/djab036.
2
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
3
Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis.BRCA1/2 突变患者行预防性子宫切除术时，是否应考虑患子宫癌的风险——系统评价和荟萃分析。
Gynecol Oncol. 2021 Mar;160(3):755-762. doi: 10.1016/j.ygyno.2020.11.034. Epub 2020 Dec 10.
4
Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis.遗传性 BRCA 基因突变携带者的子宫内膜癌：系统评价和荟萃分析。
J Minim Invasive Gynecol. 2021 May;28(5):947-956. doi: 10.1016/j.jmig.2020.11.023. Epub 2020 Nov 27.
5
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.子宫浆液性癌：分子特征、临床管理以及新的和未来的治疗方法。
Gynecol Oncol. 2021 Jan;160(1):322-332. doi: 10.1016/j.ygyno.2020.10.017. Epub 2020 Nov 5.
6
Tamoxifen and Endometrial Cancer: A Janus-Headed Drug.他莫昔芬与子宫内膜癌：一种双面性药物。
Cancers (Basel). 2020 Sep 7;12(9):2535. doi: 10.3390/cancers12092535.
7
Fallopian tube abnormalities in uterine serous carcinoma.子宫浆液性癌中的输卵管异常。
Gynecol Oncol. 2020 Aug;158(2):339-346. doi: 10.1016/j.ygyno.2020.04.707. Epub 2020 May 12.
8
Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.绝经激素治疗的类型和时机与乳腺癌风险：全球流行病学证据的个体参与者荟萃分析。
Lancet. 2019 Sep 28;394(10204):1159-1168. doi: 10.1016/S0140-6736(19)31709-X. Epub 2019 Aug 29.
9
A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients.遗传性癌症基因检测临床指南：对 165000 例高危患者中基因特异性癌症相关性和基因检测标准敏感性的队列评估。
Genet Med. 2020 Feb;22(2):407-415. doi: 10.1038/s41436-019-0633-8. Epub 2019 Aug 13.
10
Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis.《回到未来？输卵管、前驱细胞逃逸与高级别浆液性癌发生的二元模型》
Cancers (Basel). 2018 Nov 28;10(12):468. doi: 10.3390/cancers10120468.
Zotero 插件